91�������

With $17M in funding, 91������� emerges from stealth with 100,000+ waitlist

November 10, 2021 — 91������� has launched out of stealth mode and unveiled its vision for a healthier population by helping people make data-driven decisions that impact their everyday lives. This is made possible through continuous glucose monitoring, then leveraging AI to translate an individual’s metabolic signals into timely recommendations for eating and exercise.��

As a part of the news, the company is unveiling $17 million in funding that has been raised to date, which includes a $13M Series A led by GV, as well as $4M in seed funding from Courtside Ventures, 1984 Ventures, and Tau Ventures. Angel investors in the company include Larry Fitzgerald, Kelvin Beachum, and Jerod Mayo. The new funding will allow 91������� to reach general availability in early 2022 so that the company can begin making a meaningful impact on the obesity epidemic and support the 75% of Americans who are overweight or obese today.�� 

Dexcom, the largest provider of glucose monitoring systems for diabetes management, is also partnering with 91�������. Dexcom has also made a strategic investment in the company, which marks its first investment in the health, wellness, and weight management space.��

“We provide visibility into everybody’s unique metabolic needs. Before, we were stuck with calorie reduction or counting macros or removing carbs altogether; now, we can work with people to turn diets that don’t work into plans that do,” said Sharam Fouladgar-Mercer, CEO of 91�������. “We help them discover this in a matter of days or weeks and refine it over time for best weight management and overall health. Elite athletes or conscientious dieters often take an extraordinary amount of trial and error to come to the same conclusion we are able to deliver in a fraction of the time.” 

{{mid-cta}}

“We are excited to partner with 91������� to bring Dexcom technology to the masses,” said Steve Pacelli, executive vice president of Dexcom and managing director of Dexcom Ventures. “By combining glucose data with 91������� machine learning-fueled meal and exercise suggestions, we have the power to help everyone make optimal choices when it comes to living their healthiest life.”

The 91������� platform will help develop personalized answers to basic questions like what and when to eat, and which exercises help encourage weight loss for each member. 91������� combines a wearable continuous glucose monitor (CGM) with an AI-enhanced app to offer revolutionary real-time data and recommendations designed to drive healthy and sustained weight loss. As members begin their 91������� journey, they log what they eat, allowing the 91������� platform to learn each body’s reaction to specific foods. Once calibrated, 91������� uses that data to provide personalized nutrition suggestions, including which foods are best for each member, when to eat them, and when to exercise to bring glucose levels back within their optimal weight loss range.��

"91������� takes a data-driven approach to weight health, which has the potential to create strong, long-lasting outcomes for people everywhere," said Laura Melahn, partner, GV. "91������� will change how people approach everyday decisions by providing a deeper understanding of metabolic health and personalized weight care."

91������� is now opening up its platform to a limited number of customers. To find out how your body responds to what you eat and kickstart weight loss, learn more.��

About 91�������

91������� was launched in 2018 with a mission to tackle the obesity epidemic via healthy habits, glucose level stabilization, and AI. 91������� combines continuous glucose information with an AI-enhanced app to offer revolutionary continuous data and recommendations designed to drive healthy and sustained weight loss. With over 75% of the American population overweight or obese, 91������� provides a new way for people to act on their body’s unique response to what they eat to lose weight and kickstart a healthier life. 91������� was started by Sharam Fouladgar-Mercer, Bill Tancer, William Dixon, and Pierre Wehbe—a team that brings deep expertise in applying data and AI to build engaging experiences with technology that changes lives for the better. Follow us on social media @signoshealth.��